[Intravenous XXXX in large doses in the treatment of delayed ischemic neurological deficits following subarachnoid hemorrhage--results of a multi-center controlled double-blind clinical study].

@entity1 @entity2657 @entity2806 @entity2918 @entity701 @entity2553
Glucocorticoid in high dose has known to reduce vascular sensitivity to various vasoconstrictive stimuli. It inhibits phospholipase to reduce production of @entity2918 . It stabilizes the cell membrane and prevents @entity2657 . All these pharmacological effects indicate possible usefulness of this drug for the treatment of @entity2806 due to @entity2553 . Based on these theoretical backgrounds a multi-center controlled double blind clinical study was carried out. The @entity1 who showed manifestations of delayed @entity2806 due to @entity2553 were selected for this study. As soon as the clinical manifestation appeared, the @entity1 was given either 3 grams of @entity701 intravenously in a 60 ml solution or the placebo. The administration was repeated 6 times with interval of 12 hours. The @entity1 were allowed to be treated according to the independent protocol of each institute except for the maximum daily use of glucocorticoid. The effect of the therapy was evaluated at 4th, 7th day and 1 month after the initiation. The study involved 52 institutes and a total of 140 @entity1 , seventy-one @entity1 who received @entity701 (group A) and 69 @entity1 who received placebo (group P) was analysed. There were no significant differences in background data between both groups. In @entity1 with grade I, II or III on admission, the favorable effects of @entity701 were demonstrated on changes in neurological findings. In group A, there were significantly more cases of improvement at 4th day for orientation about place and @entity1 . At 1 month or on discharge group A showed significant improvement almost in every aspect of neurological findings including mental, speech and motor functions.(ABSTRACT TRUNCATED AT 250 WORDS)
